219 related articles for article (PubMed ID: 1327841)
41. Cholecystokinin-A but not cholecystokinin-B receptor stimulation induces endogenous opioid-dependent antinociceptive effects in the hot plate test in mice.
Derrien M; Noble F; Maldonado R; Roques BP
Neurosci Lett; 1993 Oct; 160(2):193-6. PubMed ID: 8247353
[TBL] [Abstract][Full Text] [Related]
42. Similar potencies of CCK-8 and its analogue BOC(Nle28;Nle31)CCK27-33 on the self-stimulation behaviour both are antagonized by a newly synthesized cyclic CCK analogue.
Heidbreder C; Roques BP; De Witte P
Neuropeptides; 1989; 13(2):89-94. PubMed ID: 2739884
[TBL] [Abstract][Full Text] [Related]
43. Ethological analysis of cholecystokinin (CCKA and CCKB) receptor ligands in the elevated plus-maze test of anxiety in mice.
Johnson NJ; Rodgers RJ
Psychopharmacology (Berl); 1996 Apr; 124(4):355-64. PubMed ID: 8739551
[TBL] [Abstract][Full Text] [Related]
44. Cholecystokinin-8S increases dynorphin B, aspartate and glutamate release in the fronto-parietal cortex of the rat via different receptor subtypes.
You ZB; Godukhin O; Goiny M; Nylander I; Ungerstedt U; Terenius L; Hökfelt T; Herrera-Marschitz M
Naunyn Schmiedebergs Arch Pharmacol; 1997 May; 355(5):576-81. PubMed ID: 9151295
[TBL] [Abstract][Full Text] [Related]
45. Characterization of YM022: its CCKB/gastrin receptor binding profile and antagonism to CCK-8-induced Ca2+ mobilization.
Saita Y; Yazawa H; Honma Y; Nishida A; Miyata K; Honda K
Eur J Pharmacol; 1994 Oct; 269(2):249-54. PubMed ID: 7851501
[TBL] [Abstract][Full Text] [Related]
46. Development of 1,4-benzodiazepine cholecystokinin type B antagonists.
Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Garsky VM; Gilbert KF; Leighton JL; Carson KL; Mellin EC
J Med Chem; 1993 Dec; 36(26):4276-92. PubMed ID: 8277510
[TBL] [Abstract][Full Text] [Related]
47. Cholecystokinin octapeptide analogues suppress food intake via central CCK-A receptors in mice.
Hirosue Y; Inui A; Teranishi A; Miura M; Nakajima M; Okita M; Nakajima Y; Himori N; Baba S; Kasuga M
Am J Physiol; 1993 Sep; 265(3 Pt 2):R481-6. PubMed ID: 8214137
[TBL] [Abstract][Full Text] [Related]
48. Central and peripheral cholecystokinin receptors in chickens differ from those in mammals.
Rodríguez-Sinovas A; Fernández AG; Goñalons E
Regul Pept; 1995 Dec; 60(1):47-54. PubMed ID: 8747783
[TBL] [Abstract][Full Text] [Related]
49. A new, highly selective CCK-B receptor radioligand ([3H][N-methyl-Nle28,31]CCK26-33): evidence for CCK-B receptor heterogeneity.
Knapp RJ; Vaughn LK; Fang SN; Bogert CL; Yamamura MS; Hruby VJ; Yamamura HI
J Pharmacol Exp Ther; 1990 Dec; 255(3):1278-86. PubMed ID: 2262906
[TBL] [Abstract][Full Text] [Related]
50. Cyclic cholecystokinin analogues that are highly selective for rat and guinea pig central cholecystokinin receptors.
Rodriguez M; Lignon MF; Galas MC; Amblard M; Martinez J
Mol Pharmacol; 1990 Sep; 38(3):333-41. PubMed ID: 1698251
[TBL] [Abstract][Full Text] [Related]
51. CCKB receptor stimulation mediates [Ca2+]i increase but no PKC activation in Jurkat T-cells.
Kaufmann R; Lindschau C; Buchner K; Ott T
Neuroreport; 1992 Aug; 3(8):697-9. PubMed ID: 1520857
[TBL] [Abstract][Full Text] [Related]
52. Properties of receptors for gastrin and CCK on gastric smooth muscle cells.
Menozzi D; Gardner JD; Jensen RT; Maton PN
Am J Physiol; 1989 Jul; 257(1 Pt 1):G73-9. PubMed ID: 2473654
[TBL] [Abstract][Full Text] [Related]
53. Cholecystokinin increases extracellular dopamine overflow in the anterior nucleus accumbens via CCK(B) receptors in the VTA assessed by in vivo voltammetry.
Reum T; Schäfer U; Marsden CA; Fink H; Morgenstern R
Neuropeptides; 1997 Feb; 31(1):82-8. PubMed ID: 9574843
[TBL] [Abstract][Full Text] [Related]
54. Effects of BOC-CCK-4 and L 365.260 on cortical 5-HT release in guinea-pigs on exposure to the elevated plus maze.
Rex A; Fink H; Marsden CA
Neuropharmacology; 1994; 33(3-4):559-65. PubMed ID: 7527129
[TBL] [Abstract][Full Text] [Related]
55. Large and prolonged in vivo response of pancreatic secretion to phenylethylamide and phenylethylester derivatives of Boc-[Nle28-Nle31]CCK(26-33) in the rat.
Nagain C; Lignon MF; Galas MC; Rodriguez M; Martinez J; Rozé C
Peptides; 1992; 13(6):1127-32. PubMed ID: 1494494
[TBL] [Abstract][Full Text] [Related]
56. CCK-JMV-180 acts as an antagonist of the CCKA receptor in the human IMR-32 neuroblastoma cell line.
Schaeffer P; Prabonnaud V; Roux M; Gully D; Herbert JM
FEBS Lett; 1994 Nov; 354(2):203-6. PubMed ID: 7957924
[TBL] [Abstract][Full Text] [Related]
57. Identification of CCK-A receptors on chief cells with use of a novel, highly selective ligand.
Pradhan TK; Qian JM; Sutliff VE; Mantey SA; Jensen RT
Am J Physiol; 1995 Apr; 268(4 Pt 1):G605-12. PubMed ID: 7733286
[TBL] [Abstract][Full Text] [Related]
58. Gastrin and CCK activate phospholipase C and stimulate pepsinogen release by interacting with two distinct receptors.
Qian JM; Rowley WH; Jensen RT
Am J Physiol; 1993 Apr; 264(4 Pt 1):G718-27. PubMed ID: 8476056
[TBL] [Abstract][Full Text] [Related]
59. Cholecystokinin-induced protection of cultured cortical neurons against glutamate neurotoxicity.
Akaike A; Tamura Y; Sato Y; Ozaki K; Matsuoka R; Miura S; Yoshinaga T
Brain Res; 1991 Aug; 557(1-2):303-7. PubMed ID: 1684128
[TBL] [Abstract][Full Text] [Related]
60. Pharmacological properties of ureido-acetamides, new potent and selective non-peptide CCKB/gastrin receptor antagonists.
Bertrand P; Böhme GA; Durieux C; Guyon C; Capet M; Jeantaud B; Boudeau P; Ducos B; Pendley CE; Martin GE
Eur J Pharmacol; 1994 Sep; 262(3):233-45. PubMed ID: 7813588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
